A procedure for studying the within-session onset of human drug discrimination.

The purpose of the present study was to develop a procedure for measuring the within-session onset of human drug discrimination. During daily sessions, under double-blind conditions, caffeine-abstinent adults ingested a letter-coded capsule containing 178 mg caffeine or placebo. Trials were presented at 30-s intervals, beginning immediately after drug ingestion and continuing for 60 min. On each trial, subjects could guess which of their two letter-coded drugs they had received by pressing a left button (for one drug) or right button (for the other drug); subjects could also press a center "no guess" button instead of guessing. Each trial ended after one button press. After each session, subjects were told which drug they had received. Subjects earned one point (worth $0.10 per point) for each correct guess. Subjects lost either 0, 1, or 10 points for each incorrect guess; the point-loss contingencies were varied in random order across sessions. Discrimination earnings accumulated across all sessions. The point-loss contingencies decreased random responding and delayed the discrimination time course. Overall, this procedure provided an orderly and relatively continuous measure of the within-session onset of drug discrimination and should have a range of applications in understanding the human behavioral pharmacology of drugs.

[1]  C. Samele,et al.  A bibliography of drug discrimination research, 1989–1991 , 1992, Behavioural pharmacology.

[2]  K. Preston Drug discrimination methods in human drug abuse liability evaluation. , 1991, British journal of addiction.

[3]  D. Overton Human drug discrimination: current limitations, future possibilities Commentary on Preston and Bigelow "Subjective and discriminative effects of drugs" , 1991, Behavioural pharmacology.

[4]  K. Preston,et al.  Subjective and discriminative effects of drugs. , 1991, Behavioural pharmacology.

[5]  S J Heishman,et al.  Low-dose caffeine discrimination in humans. , 1990, The Journal of pharmacology and experimental therapeutics.

[6]  W. Bickel,et al.  Opioid drug discrimination in humans: stability, specificity and relation to self-reported drug effect. , 1989, The Journal of pharmacology and experimental therapeutics.

[7]  W. Bickel,et al.  Drug discrimination in human postaddicts: agonist-antagonist opioids. , 1989, The Journal of pharmacology and experimental therapeutics.

[8]  H. S. Garcha,et al.  Temporal factors in drug discrimination: Experiments with nicotine , 1989, Journal of psychopharmacology.

[9]  K. Preston,et al.  Three-choice drug discrimination in opioid-dependent humans: hydromorphone, naloxone and saline. , 1987, The Journal of pharmacology and experimental therapeutics.

[10]  N. Benowitz,et al.  Improved gas chromatographic method for the determination of nicotine and cotinine in biologic fluids. , 1981, Journal of chromatography.

[11]  H. Huynh,et al.  Estimation of the Box Correction for Degrees of Freedom from Sample Data in Randomized Block and Split-Plot Designs , 1976 .

[12]  R. Griffiths,et al.  Low-dose caffeine discrimination and self-reported mood effects in normal volunteers. , 1992, Journal of the experimental analysis of behavior.

[13]  N. Ator Drug discrimination and drug stimulus generalization with anxiolytics , 1990 .

[14]  C. Spielberger,et al.  STAI manual for the State-trait anxiety inventory ("self-evaluation questionnaire") , 1970 .